Khurshida Begum to Clostridium Infections
This is a "connection" page, showing publications Khurshida Begum has written about Clostridium Infections.
Connection Strength
3.427
-
A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
Score: 0.872
-
Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob Agents Chemother. 2024 03 06; 68(3):e0162123.
Score: 0.206
-
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
Score: 0.205
-
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
Score: 0.195
-
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clin Infect Dis. 2022 09 30; 75(7):1164-1170.
Score: 0.187
-
Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings. Anaerobe. 2022 Jun; 75:102543.
Score: 0.180
-
Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
Score: 0.174
-
Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
Score: 0.170
-
Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. Anaerobe. 2021 Jun; 69:102352.
Score: 0.168
-
A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 12 01; 75(12):3635-3643.
Score: 0.165
-
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
Score: 0.163
-
PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020; 9(1):341-347.
Score: 0.156
-
Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
Score: 0.150
-
Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals. Anaerobe. 2019 Oct; 59:107-111.
Score: 0.149
-
Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
Score: 0.146
-
Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
Score: 0.142